Top Markets
Coin of the day
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Rank in Stocks #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Share Price
$59.98
Last synced: 2024-12-13
Market Cap
$1.22B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Longboard Pharmaceuticals, Inc. (LBPH)

Category

EPS for Longboard Pharmaceuticals, Inc. (LBPH)
EPS as of September 2024 TTM: $-2.24
According to Longboard Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-2.24. At the end of 2022 the company had a EPS of $-2.51 an increase over its 2021 EPS that were of $-1.62.
EPS history for Longboard Pharmaceuticals, Inc. from 2020 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-2.24 -6.28%
2023 $-2.39 -4.78%
2022 $-2.51 54.94%
2021 $-1.62 97.56%
2020 $-0.82 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -873.21%
US
$27.74 -1,338.39%
NL
$-5.29 136.16%
AU
$-7.98 256.25%
US
- -
CH